Glioblastoma Tumor Microenvironment: An Important Modulator for Tumoral Progression and Therapy Resistance

Overview

Journal Curr Issues Mol Biol

Publisher MDPI

Specialty Molecular Biology

Date 2024 Sep 27

PMID 39329940

Authors

Ligia Gabriela Tataranu

Serban Turliuc

Amira Kamel

Radu Eugen Rizea

Anica Dricu

Georgiana-Adeline Staicu

Stefania Carina Baloi

Silvia Mara Baez Rodriguez

Andrada Ioana Maria Manole

Affiliations

Soon will be listed here.

Abstract

The race to find an effective treatment for glioblastoma (GBM) remains a critical topic, because of its high aggressivity and impact on survival and the quality of life. Currently, due to GBM's high heterogeneity, the conventional treatment success rate and response to therapy are relatively low, with a median survival rate of less than 20 months. A new point of view can be provided by the comprehension of the tumor microenvironment (TME) in pursuance of the development of new therapeutic strategies to aim for a longer survival rate with an improved quality of life and longer disease-free interval (DFI). The main components of the GBM TME are represented by the extracellular matrix (ECM), glioma cells and glioma stem cells (GSCs), immune cells (microglia, macrophages, neutrophils, lymphocytes), neuronal cells, all of them having dynamic interactions and being able to influence the tumoral growth, progression, and drug resistance thus being a potential therapeutic target. This paper will review the latest research on the GBM TME and the potential therapeutic targets to form an up-to-date strategy.

Citing Articles

Prognostic Role of Pyruvate Kinase M2 in High-Grade Gliomas: A Quantitative Immunohistochemistry Study.

Tamas C, Cehan A, Kovecsi A, Tamas F, Balasa A Cureus. 2025; 17(1):e78035.

PMID: 40013192 PMC: 11862283. DOI: 10.7759/cureus.78035.

References

Ishiuchi S, Tsuzuki K, Yoshida Y, Yamada N, Hagimura N, Okado H . Blockage of Ca(2+)-permeable AMPA receptors suppresses migration and induces apoptosis in human glioblastoma cells. Nat Med. 2002; 8(9):971-8. DOI: 10.1038/nm746. View

Luksik A, Yazigi E, Shah P, Jackson C . CAR T Cell Therapy in Glioblastoma: Overcoming Challenges Related to Antigen Expression. Cancers (Basel). 2023; 15(5). PMC: 10000604. DOI: 10.3390/cancers15051414. View

Dubinski D, Wolfer J, Hasselblatt M, Schneider-Hohendorf T, Bogdahn U, Stummer W . CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients. Neuro Oncol. 2015; 18(6):807-18. PMC: 4864257. DOI: 10.1093/neuonc/nov280. View

Malkki H . Trial Watch: Glioblastoma vaccine therapy disappointment in Phase III trial. Nat Rev Neurol. 2016; 12(4):190. DOI: 10.1038/nrneurol.2016.38. View

Arrieta V, Dmello C, McGrail D, Brat D, Lee-Chang C, Heimberger A . Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment. J Clin Invest. 2023; 133(2). PMC: 9843050. DOI: 10.1172/JCI163447. View

Assimakopoulou M, Kondyli M, Gatzounis G, Maraziotis T, Varakis J . Neurotrophin receptors expression and JNK pathway activation in human astrocytomas. BMC Cancer. 2007; 7:202. PMC: 2180182. DOI: 10.1186/1471-2407-7-202. View

Sener U, Ruff M, Campian J . Immunotherapy in Glioblastoma: Current Approaches and Future Perspectives. Int J Mol Sci. 2022; 23(13). PMC: 9266573. DOI: 10.3390/ijms23137046. View

Chen C, Jing W, Chen Y, Wang G, Abdalla M, Gao L . Intracavity generation of glioma stem cell-specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy. Sci Transl Med. 2022; 14(656):eabn1128. DOI: 10.1126/scitranslmed.abn1128. View

Hinshaw D, Shevde L . The Tumor Microenvironment Innately Modulates Cancer Progression. Cancer Res. 2019; 79(18):4557-4566. PMC: 6744958. DOI: 10.1158/0008-5472.CAN-18-3962. View

10.

Marino S, Menna G, Di Bonaventura R, Lisi L, Mattogno P, Figa F . The Extracellular Matrix in Glioblastomas: A Glance at Its Structural Modifications in Shaping the Tumoral Microenvironment-A Systematic Review. Cancers (Basel). 2023; 15(6). PMC: 10046791. DOI: 10.3390/cancers15061879. View

11.

Bianconi A, Palmieri G, Aruta G, Monticelli M, Zeppa P, Tartara F . Updates in Glioblastoma Immunotherapy: An Overview of the Current Clinical and Translational Scenario. Biomedicines. 2023; 11(6). PMC: 10295612. DOI: 10.3390/biomedicines11061520. View

12.

Erices J, Bizama C, Niechi I, Uribe D, Rosales A, Fabres K . Glioblastoma Microenvironment and Invasiveness: New Insights and Therapeutic Targets. Int J Mol Sci. 2023; 24(8). PMC: 10139189. DOI: 10.3390/ijms24087047. View

13.

Wu H, Yang L, Liu H, Zhou D, Chen D, Zheng X . Exploring the efficacy of tumor electric field therapy against glioblastoma: An in vivo and in vitro study. CNS Neurosci Ther. 2021; 27(12):1587-1604. PMC: 8611775. DOI: 10.1111/cns.13750. View

14.

Musatova O, Rubtsov Y . Effects of glioblastoma-derived extracellular vesicles on the functions of immune cells. Front Cell Dev Biol. 2023; 11:1060000. PMC: 10028257. DOI: 10.3389/fcell.2023.1060000. View

15.

Marcus H, Carpenter K, Price S, Hutchinson P . In vivo assessment of high-grade glioma biochemistry using microdialysis: a study of energy-related molecules, growth factors and cytokines. J Neurooncol. 2009; 97(1):11-23. DOI: 10.1007/s11060-009-9990-5. View

16.

Logun M, Wynens K, Simchick G, Zhao W, Mao L, Zhao Q . Surfen-mediated blockade of extratumoral chondroitin sulfate glycosaminoglycans inhibits glioblastoma invasion. FASEB J. 2019; 33(11):11973-11992. PMC: 6902699. DOI: 10.1096/fj.201802610RR. View

17.

Driessens G, Kline J, Gajewski T . Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev. 2009; 229(1):126-44. PMC: 3278040. DOI: 10.1111/j.1600-065X.2009.00771.x. View

18.

Popescu A, Alexandru O, Brindusa C, Purcaru S, Tache D, Tataranu L . Targeting the VEGF and PDGF signaling pathway in glioblastoma treatment. Int J Clin Exp Pathol. 2015; 8(7):7825-37. PMC: 4555675. View

19.

Wick W, Puduvalli V, Chamberlain M, van den Bent M, Carpentier A, Cher L . Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol. 2010; 28(7):1168-74. PMC: 2834468. DOI: 10.1200/JCO.2009.23.2595. View

20.

van Vuurden D, Yazdani M, Bosma I, Broekhuizen A, Postma T, Heimans J . Attenuated AMPA receptor expression allows glioblastoma cell survival in glutamate-rich environment. PLoS One. 2009; 4(6):e5953. PMC: 2693929. DOI: 10.1371/journal.pone.0005953. View